Results 81 to 90 of about 52,376 (272)

New treatments for myasthenia: a focus on antisense oligonucleotides [PDF]

, 2013
Corrado Angelini,1 Sara Martignago,2 Michela Bisciglia21IRCCS S Camillo, Via Alberoni, Venice, Italy; 2Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padova, ItalyAbstract: Autoimmune myasthenia gravis (MG) is a ...
Bisciglia M, Angelini C., Angelini C, Martignago S, Martignago S., Bisciglia M.   +5 more
core   +1 more source

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

GENERAL ETIOLOGY OF NERVOUS ACTIVITY DISTURBANCES. NEUROGENIC PATHOLOGICAL SYNDROMES

Вопросы современной педиатрии, 2013
The most clinically significant causes and the main links of mechanisms of development of neurogenic pathological syndromes are discussed in this lecture.
P. F. Litvitskii
doaj   +1 more source

Muscle‐Specific Kinase Signaling and Its Therapeutic Potential

Muscle &Nerve, EarlyView.
ABSTRACT The function of the neuromuscular junction (NMJ) is compromised in many neuromuscular diseases (NMDs) such as autoimmune or congenital myasthenia gravis (MG), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and muscular dystrophies.
Stine Marie Jensen, Dana L. E. Vergoossen, Maartje G. Huijbers   +2 more
wiley   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone

Discover Oncology
Objective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical ...
Shanshan Gu, Xu Wang, Hongxia Yang, Yaxuan Wang, Congya Yan, Xiaoting Lin, Peng Liu, Lu Liu, Li Meng, Guoyan Qi   +9 more
doaj   +1 more source

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza, Elena Wolff, Michael Chou, Vera Bril, Hans Katzberg, Ahmed Bayoumi, Carolina Barnett‐Tapia   +6 more
wiley   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology
Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG)
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
doaj   +1 more source

Response Shift and Item Interpretation: Two Caveats for Using Minimal Symptom Expression as a Treatment Goal in Generalised Myasthenia Gravis. [PDF]

Eur J Neurol
European Journal of Neurology, Volume 33, Issue 9, September 2026.
Li HF, Li Q, Guan YZ, Yang H.
europepmc   +2 more sources

Cytokine Profiles in Myasthenia Gravis Subgroups and the Lack of Any Effect of Immunosuppression

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Myasthenia gravis (MG) is a clinically and immunologically heterogeneous autoimmune disease and there is little known about the differential effects of cytokines in disease subgroups. This study aimed to compare serum cytokine profiles across distinct MG subgroups, including early‐onset MG (EOMG), late‐onset MG (LOMG), muscle‐
Merve Cebi, Hacer Durmus, Arman Çakar, Mehmet Güven Günver, Yesim Parman, Feza Deymeer, Güher Saruhan‐Direskeneli   +6 more
wiley   +1 more source